Pages that link to "Q42945863"

The following pages link to Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease (Q42945863):

Displaying 41 items.

• Autophagy in kidney disease and aging: lessons from rodent models (Q26744223) (← links)
• The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies (Q27026481) (← links)
• Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease (Q27320627) (← links)
• Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat (Q28573157) (← links)
• PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease (Q28742454) (← links)
• An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. (Q34074513) (← links)
• Rosiglitazone Inhibits Transforming Growth Factor-β1 Mediated Fibrogenesis in ADPKD Cyst-Lining Epithelial Cells (Q34103484) (← links)
• An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease (Q34865335) (← links)
• The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease (Q34979740) (← links)
• Autosomal dominant polycystic kidney disease in children (Q35596375) (← links)
• Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease (Q35655072) (← links)
• Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease (Q35917458) (← links)
• The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees (Q36003176) (← links)
• Emerging role of autophagy in kidney function, diseases and aging (Q36194753) (← links)
• Folate-conjugated rapamycin slows progression of polycystic kidney disease (Q36280381) (← links)
• Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside (Q36471777) (← links)
• Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease (Q37691863) (← links)
• Diagnosis and management of childhood polycystic kidney disease (Q37806654) (← links)
• Somatostatin analogues for treatment of polycystic liver disease (Q37824573) (← links)
• Putative roles of cilia in polycystic kidney disease (Q37876523) (← links)
• mTOR signaling in polycystic kidney disease (Q37903128) (← links)
• Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications (Q38002007) (← links)
• mTOR controls kidney epithelia in health and disease (Q38185017) (← links)
• Pharmacological management of polycystic kidney disease (Q38199755) (← links)
• An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease. (Q38540557) (← links)
• Protection From Apoptotic Cell Death During Cold Storage Followed by Rewarming in 13-Lined Ground Squirrel Tubular Cells: The Role of Prosurvival Factors X-Linked Inhibitor of Apoptosis and PhosphoAkt (Q38603730) (← links)
• Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease (Q38733796) (← links)
• Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. (Q38960067) (← links)
• Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin (Q39320572) (← links)
• Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis. (Q41247634) (← links)
• Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease (Q41426265) (← links)
• Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease. (Q41897689) (← links)
• Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD. (Q52668626) (← links)
• Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease (Q60301586) (← links)
• Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism (Q84403251) (← links)
• Slow the pace of renal failure in autosomal dominant polycystic kidney disease: hopes and disappointments (Q85027384) (← links)
• Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study (Q89029564) (← links)
• Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges (Q90230633) (← links)
• Metabolism and mitochondria in polycystic kidney disease research and therapy (Q91013837) (← links)
• Regression of Peritubular Capillaries Coincides with Angiogenesis and Renal Cyst Growth in Experimental Polycystic Kidney Disease (Q91840007) (← links)
• RAPAMYCIN INCREASES LENGTH AND MECHANOSENSORY FUNCTION OF PRIMARY CILIA IN RENAL EPITHELIAL AND VASCULAR ENDOTHELIAL CELLS (Q94363723) (← links)